Ypsilon Therapeutics has been awarded $2.7 million in seed funding from Cancer Prevention & Research Institute of Texas (CPRIT). The award will allow Ypsilon to advance its lead therapeutic program, a next-generation T-cell receptor mimic (TCRm) antibody, to drug candidate nomination, with the aim of developing treatments for patients with solid tumors, such as triple-negative breast cancer, non-small-cell lung cancer and gastric cancer.
California Institute for Regenerative Medicine (CIRM) has awarded a $5.8 million translational research grant to a scientist at the University of California, Los Angeles (UCLA) to further support the development of a hematopoietic stem cell (HSC) gene therapy to treat Angelman syndrome, including preparation of a pre-IND package submission to the FDA.
Chugai Pharmaceutical Co. Ltd. has signed a collaboration agreement with GSK plc’s Global Health Unit (GSK GH) for the development of an anti-dengue virus antibody. Under this agreement, GSK GH will perform activities and explore potential funding for the initiation of clinical studies of AID-351.
Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), is still one of the most lethal cancers and does not yet have an effective therapy. There is an urgent need to identify therapeutic targets to improve therapies in PDAC. Now, researchers in France have published data regarding the nucleolin antagonist N6L in combination with paclitaxel as a promising therapeutic avenue for treating PDAC.
Understanding the mechanisms of resistance to cancer treatments is necessary to find effective therapies at different stages of the disease. Scientists at UT Southwestern Medical Center studied the most frequent mutation in pancreatic ductal adenocarcinoma (PDAC), identified an escape route to a therapy in clinical trials, blocked it with another experimental compound and reduced tumors in mice.
Implanted patches of iPS cell-derived heart muscle integrated with heart tissue in a primate model of heart failure, and in patients being treated in a clinical trial, marks progress toward a potential option for patients with advanced heart failure.
Pyrimidine compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors and reported to be useful for the treatment of cancer have been disclosed in a recent Asieris Pharmaceuticals Co. Ltd. patent.
Work at Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has led to the identification of heteroaromatic ring compounds acting as membrane-associated tyrosine-and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.
Recent Engrail Therapeutics Inc. patents describe new deuterated nemonapride analogues potentially useful for the treatment of depression and schizophrenia.
Novartis AG has synthesized new sodium channel protein type 5 subunit alpha (SCN5A; Nav1.5) blockers reported to be useful for the treatment of heart failure, long QT syndrome, hypertrophic cardiomyopathy, angina pectoris, myotonia, ventricular tachycardia, atrial and ventricular fibrillation, among others.
RSS
